Selected research
Market Structure
Global Coagulation Factor VIIa Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Coagulation Factor VIIa market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Coagulation Factor VIIa is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Coagulation Factor VIIa is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Coagulation Factor VIIa is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Coagulation Factor VIIa is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Coagulation Factor VIIa include Novo Nordisk, LFB SA HEMA Biologics, GENERIUM and AryoGen Pharmed, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Coagulation Factor VIIa market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Coagulation Factor VIIa and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Coagulation Factor VIIa sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Coagulation Factor VIIa market size, projected growth trends, production technologies, key applications, and end-use industries.
Coagulation Factor VIIa Segment by Company
Novo Nordisk
LFB SA HEMA Biologics
GENERIUM
AryoGen Pharmed
Coagulation Factor VIIa Segment by Type
Prefilled Syringe
Vial
Coagulation Factor VIIa Segment by Application
Congenital Hemophilia
Acquired Hemophilia
Other
Coagulation Factor VIIa Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Coagulation Factor VIIa market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Coagulation Factor VIIa and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Coagulation Factor VIIa.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Coagulation Factor VIIa market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Coagulation Factor VIIa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Coagulation Factor VIIa in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Coagulation Factor VIIa in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Prefilled Syringe
- Vial
Applications
- Congenital Hemophilia
- Acquired Hemophilia
- Other
Companies covered
- Novo Nordisk
- LFB SA HEMA Biologics
- GENERIUM
- AryoGen Pharmed
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Coagulation Factor VIIa Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Coagulation Factor VIIa Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Coagulation Factor VIIa Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Coagulation Factor VIIa Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Coagulation Factor VIIa Market Dynamics
- 2.1 Coagulation Factor VIIa Industry Trends
- 2.2 Coagulation Factor VIIa Industry Drivers
- 2.3 Coagulation Factor VIIa Industry Opportunities and Challenges
- 2.4 Coagulation Factor VIIa Industry Restraints
3 Coagulation Factor VIIa Market by Manufacturers
- 3.1 Global Coagulation Factor VIIa Revenue by Manufacturers (2021-2026)
- 3.2 Global Coagulation Factor VIIa Sales by Manufacturers (2021-2026)
- 3.3 Global Coagulation Factor VIIa Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Coagulation Factor VIIa Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Coagulation Factor VIIa Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Coagulation Factor VIIa Manufacturers, Product Type & Application
- 3.7 Global Coagulation Factor VIIa Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Coagulation Factor VIIa Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Coagulation Factor VIIa Players Market Share by Revenue in 2025
- 3.8.3 2025 Coagulation Factor VIIa Tier 1, Tier 2, and Tier 3
4 Coagulation Factor VIIa Market by Type
- 4.1 Coagulation Factor VIIa Type Introduction
- 4.1.1 Prefilled Syringe
- 4.1.2 Vial
- 4.2 Global Coagulation Factor VIIa Sales by Type
- 4.2.1 Global Coagulation Factor VIIa Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Coagulation Factor VIIa Sales by Type (2021-2032)
- 4.2.3 Global Coagulation Factor VIIa Sales Market Share by Type (2021-2032)
- 4.3 Global Coagulation Factor VIIa Revenue by Type
- 4.3.1 Global Coagulation Factor VIIa Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Coagulation Factor VIIa Revenue by Type (2021-2032)
- 4.3.3 Global Coagulation Factor VIIa Revenue Market Share by Type (2021-2032)
5 Coagulation Factor VIIa Market by Application
- 5.1 Coagulation Factor VIIa Application Introduction
- 5.1.1 Congenital Hemophilia
- 5.1.2 Acquired Hemophilia
- 5.1.3 Other
- 5.2 Global Coagulation Factor VIIa Sales by Application
- 5.2.1 Global Coagulation Factor VIIa Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Coagulation Factor VIIa Sales by Application (2021-2032)
- 5.2.3 Global Coagulation Factor VIIa Sales Market Share by Application (2021-2032)
- 5.3 Global Coagulation Factor VIIa Revenue by Application
- 5.3.1 Global Coagulation Factor VIIa Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Coagulation Factor VIIa Revenue by Application (2021-2032)
- 5.3.3 Global Coagulation Factor VIIa Revenue Market Share by Application (2021-2032)
6 Global Coagulation Factor VIIa Sales by Region
- 6.1 Global Coagulation Factor VIIa Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Coagulation Factor VIIa Sales by Region (2021-2032)
- 6.2.1 Global Coagulation Factor VIIa Sales by Region (2021-2026)
- 6.2.2 Global Coagulation Factor VIIa Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Coagulation Factor VIIa Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Coagulation Factor VIIa Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Coagulation Factor VIIa Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Coagulation Factor VIIa Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Coagulation Factor VIIa Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Coagulation Factor VIIa Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Coagulation Factor VIIa Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Coagulation Factor VIIa Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Coagulation Factor VIIa Revenue by Region
- 7.1 Global Coagulation Factor VIIa Revenue by Region
- 7.1.1 Global Coagulation Factor VIIa Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Coagulation Factor VIIa Revenue by Region (2021-2026)
- 7.1.3 Global Coagulation Factor VIIa Revenue by Region (2027-2032)
- 7.1.4 Global Coagulation Factor VIIa Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Coagulation Factor VIIa Revenue (2021-2032)
- 7.2.2 North America Coagulation Factor VIIa Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Coagulation Factor VIIa Revenue (2021-2032)
- 7.3.2 Europe Coagulation Factor VIIa Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Coagulation Factor VIIa Revenue (2021-2032)
- 7.4.2 Asia-Pacific Coagulation Factor VIIa Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Coagulation Factor VIIa Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Coagulation Factor VIIa Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Novo Nordisk
- 8.1.1 Novo Nordisk Company Information
- 8.1.2 Novo Nordisk Business Overview
- 8.1.3 Novo Nordisk Coagulation Factor VIIa Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Novo Nordisk Coagulation Factor VIIa Product Portfolio
- 8.1.5 Novo Nordisk Recent Developments
- 8.2 LFB SA HEMA Biologics
- 8.2.1 LFB SA HEMA Biologics Company Information
- 8.2.2 LFB SA HEMA Biologics Business Overview
- 8.2.3 LFB SA HEMA Biologics Coagulation Factor VIIa Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 LFB SA HEMA Biologics Coagulation Factor VIIa Product Portfolio
- 8.2.5 LFB SA HEMA Biologics Recent Developments
- 8.3 GENERIUM
- 8.3.1 GENERIUM Company Information
- 8.3.2 GENERIUM Business Overview
- 8.3.3 GENERIUM Coagulation Factor VIIa Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 GENERIUM Coagulation Factor VIIa Product Portfolio
- 8.3.5 GENERIUM Recent Developments
- 8.4 AryoGen Pharmed
- 8.4.1 AryoGen Pharmed Company Information
- 8.4.2 AryoGen Pharmed Business Overview
- 8.4.3 AryoGen Pharmed Coagulation Factor VIIa Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 AryoGen Pharmed Coagulation Factor VIIa Product Portfolio
- 8.4.5 AryoGen Pharmed Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Coagulation Factor VIIa Value Chain Analysis
- 9.1.1 Coagulation Factor VIIa Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Coagulation Factor VIIa Production Mode & Process
- 9.2 Coagulation Factor VIIa Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Coagulation Factor VIIa Distributors
- 9.2.3 Coagulation Factor VIIa Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst